Roche (Genentech) entered into a $1 billion deal with NewLink Genetics, a company with an IDO (indoleamine 2,3-dioxygenase) inhibitor. Continue reading
Immunotherapy of Cancer: Roche & NewLink $1 Billion Deal for IDO Inhibition
Leave a reply